[
    {
        "file_name": "HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_Development Agreement.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Harpoon shall provide, and shall use commercially reasonable efforts to cause its Third Party manufacturers to provide (including by using commercially reasonable efforts to negotiate contractual obligations for such Third Party manufacturers to do so under agreements entered into following the Effective Date), all reasonable assistance requested by AbbVie to enable AbbVie (or its Affiliate or designated Third Party manufacturer, as applicable) to implement the Manufacturing Process at the facility designated by AbbVie.",
                "changed_text": "Harpoon shall provide, and shall use commercially reasonable efforts to cause its Third Party manufacturers to provide (including by using commercially reasonable efforts to negotiate contractual obligations for such Third Party manufacturers to do so under agreements entered into following the Effective Date), all reasonable assistance requested by AbbVie to enable AbbVie (or its Affiliate or designated Third Party manufacturer, as applicable) to implement the Production Process at the facility designated by AbbVie.",
                "explanation": "The terms “Manufacturing Process” and “Production Process” are used interchangeably without defining whether they are the same or different, potentially leading to confusion and conflicting obligations.",
                "location": "Section 4.5.2"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Where a Harpoon Patent or Joint Patent [***]. Harpoon shall [***] with regard to the preparation, filing, prosecution, and maintenance of such Harpoon Patents or Joint Patents, including by providing AbbVie with a copy of material communications to and from any patent authority in the Territory regarding such Harpoon Patents or Joint Patents, and by providing AbbVie drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for AbbVie to review and comment thereon.",
                "changed_text": "Where a Harpoon Patent or Joint Patent [***]. Harpoon shall [***] with regard to the preparation, filing, prosecution, and maintenance of such Harpoon Patents or Joint Patents, including by providing AbbVie with a copy of material communications to and from any Intellectual Property Office in the Territory regarding such Harpoon Patents or Joint Patents, and by providing AbbVie drafts of any material filings or responses to be made to such Intellectual Property Office in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for AbbVie to review and comment thereon.",
                "explanation": "The terms “patent authority” and “Intellectual Property Office” are used interchangeably without defining whether they are the same or different, potentially leading to confusion and conflicting obligations.",
                "location": "Section 7.2.1"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Except as otherwise expressly provided herein, termination of this Agreement (either in its entirety or with respect to one (1) or more country(ies) or other jurisdiction(s)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.",
                "changed_text": "Except as otherwise expressly provided herein, cancellation of this Agreement (either in its entirety or with respect to one (1) or more country(ies) or other jurisdiction(s)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.",
                "explanation": "The terms “termination” and “cancellation” are used interchangeably without defining whether they are the same or different, potentially leading to confusion and conflicting obligations.",
                "location": "Section 12.9"
            }
        ]
    }
]